New court documents are said to provide new evidence of the US Drug Enforcement Administration’s bias against cannabis rescheduling, a process which it is overseeing.
A biopharmaceutical company is suing the Drug Enforcement Administration (DEA) over what it called unjustified delays to its application to
The Drug Enforcement Agency’s (DEA) Administrator, Anne Milgram, has come under fire from GOP congressmen over the apparent divergence of
Reports from last week suggesting that the US Drug Enforcement Administration (DEA) would support recommendations for cannabis rescheduling were not
We won’t spam you
